Weight management at FRZN is a prescription program directed by a board certified nurse practitioner. Care begins with a medical evaluation and baseline labs where indicated, followed by an individualized titration schedule and scheduled monthly follow up visits to track your response, tolerability, and safety. Treatment is dispensed only after screening confirms you are an appropriate candidate, and your plan is adjusted over time based on how you respond.

Semaglutide is a glucagon like peptide 1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone your gut releases after eating, and by activating GLP-1 receptors it increases glucose dependent insulin secretion, moderates glucagon release, and slows gastric emptying. Clinically, this reduces appetite and prolongs the feeling of fullness, which supports a sustained reduction in caloric intake. In clinical trials, semaglutide produced significant, dose dependent weight reduction when paired with nutrition and lifestyle changes.

Semaglutide is given as a once weekly subcutaneous injection. Treatment starts at a low dose and increases in stages over several weeks, which reduces gastrointestinal side effects and gives your body time to adjust. Your schedule is individualized and advanced only once the current dose is well tolerated. Many patients notice appetite changes within the first few weeks, with progressive weight reduction over the following months as the dose reaches its effective range.

Where NAD+ fits in

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell and central to mitochondrial energy production and cellular repair. Within this program it is available as an adjunct to support energy and metabolic function during a period of reduced intake. NAD+ is not a weight loss medication and does not induce fat loss. It is offered strictly as supportive care alongside the primary therapy.

Candidacy and screening

Candidacy is determined at your evaluation based on your medical history, current medications, and clinical goals. Semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and it is used with added caution in those with a history of pancreatitis, gallbladder disease, or significant gastrointestinal conditions. It is not used during pregnancy or while trying to conceive. A complete review of your history is done before any prescription is issued.

Monitoring and side effects

After starting, you will have scheduled follow ups to assess your response, review tolerability, and adjust your dose as appropriate. The most common side effects are gastrointestinal, primarily nausea, and tend to occur early and around dose increases; they are usually mild and improve as your body adapts. Less common and rare effects, along with the warning signs to watch for, are reviewed with you in detail before treatment begins. You will also receive clear instruction on injection technique, medication storage, and what to report between visits.